Back to news

ITT Reports Third Quarter 2026 EPS of $1.38 and Adjusted EPS of $2.26

Business Wire•04/11/2026•16:30 ET
0

Key Highlights

  • ➤Revenue $1.4 billion, up 44%, with 8% organic growth
  • ➤Adjusted EPS $2.26, up 20%, while reported EPS fell 15%
  • ➤Full-year adjusted EPS guidance raised to $8.54-$8.62
  • ➤Orders increased 58%, including 20% organic growth, driven by SPX FLOW
  • ➤Free cash flow rose 87% to $288.4 million
  • ➤Davide Barbon appointed to lead Connect & Control Technologies immediately

Expert Statements

Luca Savi, Chief Executive Officer and President of ITT

“ITTers around the world delivered yet another strong quarter as they executed relentlessly across the business. Our teams continue to win in the market, whilst our acquisitions are enhancing the strength of our portfolio and compounding ITT's long-term value creation. At SPX FLOW, we are executing with discipline and speed, delivering high-single-digit growth and capturing cost synergies ahead of schedule. We are unlocking revenue synergies as we leverage our expanded capabilities, global reach and customer relationships. And with a healthy backlog and orders momentum, we are well-positioned to continue driving growth and margin expansion next year whilst building an even stronger ITT”

Luca Savi, Chief Executive Officer and President of ITT

“Davide is a proven leader and disciplined operator with a strong track record of delivering results. Since taking over Motion Technologies, he has built a culture of continuous improvement that has enabled the business to continuously and consistently outperform its markets through share gains, operational excellence and productivity. Bringing our highest growth potential business with the highest margin potential under Davide’s purview creates an opportunity to accelerate performance within CCT.”

ITT Reports Third Quarter 2026 EPS of $1.38 and Adjusted EPS of $2.26

* Orders increased 58%, 20% organic, driven by the SPX FLOW acquisition, and strength in aerospace and defense, flow projects and biopharma, respectively

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in